TNGX

TNGX is experiencing High-Conviction Price Discovery driven by the acceleration of its lead PRMT5 inhibitor, vopimetostat, into late-stage clinical trials. Recent analyst upgrades to the $27-$28 range and a strategic combination trial agreement with Erasca have solidified strong institutional backing. Despite significant insider selling from the R&D President at the $25 level, the stock's PERFECT_STACK signals indicate aggressive Institutional Absorption of these shares. Supported by a highly liquid RISK_ON macro regime with low credit spreads, risk capital is confidently flowing into this high-beta oncology catalyst.